Pharmaceuticals, Biotechnology and Life Sciences
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab)…
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on…
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations…
Leadership team addition to drive strategic long-term value creation and partnering strategySOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE)…
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the…
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company…
— Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE)…
PISCATAWAY, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) — IMPALA, a global consortium dedicated to advancing digital and analytics-driven quality in…
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing…